BioMarin Announces Initiation of Clinical Assessment Program for Morquio A Syndrome
...A Mucopolysaccharidosis IVA (MPS IVA, also known as Morquio A Syndrome) is a disease characterized by deficient activity of N-acetylgalactosamine-6- sulfatase (GALNS) causing excessive lysosomal storage of keratan sulfate (KS). This excessive storage causes a systemic skeletal dysplasia, short stature, and j...Mayo Clinic identifies treatment target for liver cancer recurrence and survival
...urrence. But Mayo Clinic Cancer Center, in collaboration with the National Cancer Institute, reports in the April issue of Hepatology that the protein sulfatase 2 (SULF2) may provide one of the keys needed to begin the design of new therapies. Mayo Clinic Cancer Center leads the field in researching the imp...Tailor-made recombinant proteins in mammals
...lglycine. "Formyl" is another name for a simple aldehyde group. "So all we had to do was clone the nucleotides encoding those six residues from the sulfatase sequence into the DNA of the target protein we want to produce, at the site corresponding to where we wanted the chemical modification to occur." Bert...HWI scientist first in world to unravel structure of key breast cancer target enzyme
...structures determined by the Ghosh lab as part of this project were estrone sulfatase (2003) and 17beta-hydroxysteroid dehydrogenase type 1 (1996). All three enz... of those complexes. What Was The Project History? The aromatase and sulfatase projects were started at HWI by Dr. Yoshio Osawa more than 30 years ago. Hi...BioMarin Announces Program for ERT for Treatment of MPS IVA - Morquio A Syndrome
...A Mucopolysaccharidosis IVA (MPS IVA, also known as Morquio A Syndrome) is a disease characterized by deficient activity of N-acetylgalactosamine-6- sulfatase (GALNS) causing excessive lysosomal storage of keratan sulfate (KS). This excessive storage causes a systemic skeletal dysplasia, short stature, and j...